Literature DB >> 12234944

Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells.

Senthil Kumar Venugopal1, Sridevi Devaraj, Ivan Yuhanna, Philip Shaul, Ishwarlal Jialal.   

Abstract

BACKGROUND: C-reactive protein (CRP), the prototypic marker of inflammation, has been shown to be an independent predictor of cardiovascular events. Endothelial nitric oxide synthase (eNOS) deficiency is a pivotal event in atherogenesis. METHODS AND
RESULTS: We tested the effect of CRP on eNOS expression and bioactivity in cultured human aortic endothelial cells (HAECs). CRP decreased eNOS mRNA, protein abundance, and enzyme activity in HAECs. Furthermore, eNOS bioactivity assayed by cyclic GMP levels was significantly reduced by CRP. Preincubation of cells with CRP also significantly increased the adhesion of monocytes to HAECs.
CONCLUSION: CRP causes a direct reduction in eNOS expression and bioactivity in HAECs, further supporting its role in atherogenesis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12234944     DOI: 10.1161/01.cir.0000033116.22237.f9

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  169 in total

1.  C-reactive protein and complement factor H in aged human eyes and eyes with age-related macular degeneration.

Authors:  Imran A Bhutto; Takayuki Baba; Carol Merges; Vikash Juriasinghani; D Scott McLeod; Gerard A Lutty
Journal:  Br J Ophthalmol       Date:  2011-06-01       Impact factor: 4.638

Review 2.  Enhanced external counterpulsation for ischemic heart disease: a look behind the curtain.

Authors:  Randy W Braith; Darren P Casey; Darren T Beck
Journal:  Exerc Sport Sci Rev       Date:  2012-07       Impact factor: 6.230

Review 3.  C-reactive protein and risk of cardiovascular disease: evidence and clinical application.

Authors:  Paul M Ridker; Shari S Bassuk; Peter P Toth
Journal:  Curr Atheroscler Rep       Date:  2003-09       Impact factor: 5.113

Review 4.  Do statins offer therapeutic potential in inflammatory arthritis?

Authors:  I B McInnes; D W McCarey; N Sattar
Journal:  Ann Rheum Dis       Date:  2004-12       Impact factor: 19.103

5.  Prehypertensive African-American women have preserved nitric oxide and renal function but high cardiovascular risk.

Authors:  Deborah L Feairheller; Kathleen M Sturgeon; Keith M Diaz; Praveen Veerabhadrappa; Sheara T Williamson; Deborah L Crabbe; Michael D Brown
Journal:  Kidney Blood Press Res       Date:  2010-07-13       Impact factor: 2.687

6.  Biochemical predictors of cardiac rhythm at 1 year follow-up in patients with non-valvular atrial fibrillation.

Authors:  Mónica Acevedo; Ramón Corbalán; Sandra Braun; Jaime Pereira; Ilse González; Carlos Navarrete
Journal:  J Thromb Thrombolysis       Date:  2012-02-03       Impact factor: 2.300

7.  Increased myocardial prevalence of C-reactive protein in human coronary heart disease: direct effects on microvessel density and endothelial cell survival.

Authors:  Mandar S Joshi; Liyue Tong; Angela C Cook; Brandon L Schanbacher; Hong Huang; Bing Han; Leona W Ayers; John Anthony Bauer
Journal:  Cardiovasc Pathol       Date:  2012-01-28       Impact factor: 2.185

8.  Cholecalciferol supplementation alters calcitriol-responsive monocyte proteins and decreases inflammatory cytokines in ESRD.

Authors:  Jason R Stubbs; Arun Idiculla; Joyce Slusser; Rochelle Menard; L Darryl Quarles
Journal:  J Am Soc Nephrol       Date:  2009-12-10       Impact factor: 10.121

9.  Vitamin C treatment reduces elevated C-reactive protein.

Authors:  Gladys Block; Christopher D Jensen; Tapashi B Dalvi; Edward P Norkus; Mark Hudes; Patricia B Crawford; Nina Holland; Ellen B Fung; Laurie Schumacher; Paul Harmatz
Journal:  Free Radic Biol Med       Date:  2008-10-10       Impact factor: 7.376

10.  C-reactive protein reduces protein S-nitrosylation in endothelial cells.

Authors:  Xinhong Wang; Weimin Liu; Yue Wu; Xiaojun Liu; Xiao Liang; Zhaofei Wan; Nanping Wang; Zuyi Yuan
Journal:  Mol Cell Biochem       Date:  2012-12-09       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.